The Surfers are joined by Naim Alkhouri, Laurent Castera and Veronica Miller in three distinct interviews on the topic of the recent FDA workshop around NIT development and the future of the field.
Surfing NASH returns to its regular podcast schedule with a review of the recently concluded Paris NASH meeting. Presenters and KOLs Scott Friedman and Laurent Castera join Jörn Schattenberg, Louise Campbell and Roger Green for a fascinating final conversation which raises new and interesting topics covered at the event.
Surfing NASH returns to its regular podcast schedule with a review of the recently concluded Paris NASH meeting. Presenters and KOLs Scott Friedman and Laurent Castera join Jörn Schattenberg, Louise Campbell and Roger Green for a conversation around the complex challenges in adequately assessing and treating patients.
Surfing NASH returns to its regular podcast schedule with a review of the recently concluded Paris NASH meeting. Presenters and KOLs Scott Friedman and Laurent Castera join Jörn Schattenberg, Louise Campbell and Roger Green for a fascinating conversation that dives deeper into emerging questions surrounding the use of NITs in a landscape which features drug approval.
Surfing NASH returns to its regular podcast schedule with a review of the recently concluded Paris NASH meeting. Presenters and KOLs Scott Friedman and Laurent Castera join Jörn Schattenberg, Louise Campbell and Roger Green for a fascinating session that focuses largely on important and emerging questions surrounding the use of NITs in a landscape which features drug approval. This opening conversation highlights the different presentations delivered by the guests followed by discussion around the liver as a regenerative organ and the use and limitations of NITs.
This week, Surfing NASH looks back at a Season 3 episode that remains particularly relevant in light of recent stories on new nomenclature and therapeutic developments for liver disease. An all-star panel of liver nurses and advanced nurse practitioners join Louise Campbell and Stephen Harrison to explore the myriad ways allied health experts can play a broader role in NASH education and patient management.
The Surfers (Jörn Schattenberg, Louise Campbell and Roger Green) discuss the big stories thus far for 2023 and share previews of what to expect from the SurfingNASH program in the coming months. This conversation introduces two topics to expound on which standout amid a year that proves to be rife with rich, new information.
On the final morning of the 2022 AASLD Liver Meeting, Stephen Harrison, Sven Francque, Jörn Schattenberg, Ian Rowe, Jeff McIntyre and Roger Green discussed their key takeaways and impressions. Stephen leads this conversation From the Vault to highlight his presentation of results from Akero Therapeutics’ Phase 2b HARMONY Study.
Stephen Harrison, Mazen Noureddin, Jörn Schattenberg, Louise Campbell and Roger Green unpack compelling drug development stories from this month’s EASL Congress and ADA meetings. This final conversation continues on the subject of evaluating the GLP-1 drug class and its potential impact on lean muscle loss. The final question of Season 4, Episode 34 considers the big picture scope of what has been learned in the last month that might affect research or conceptual thinking going forward.
Stephen Harrison, Mazen Noureddin, Jörn Schattenberg, Louise Campbell and Roger Green unpack compelling drug development stories from this month’s EASL Congress and ADA meetings. This conversation considers results from the Phase 2b study for the dual GLP-1/glucagon agonist pemvidutide, which wanders into the importance of the actual GLP-1-to-glucagon impact ratio, potentially significant safety signals that remain to be fully studied, and the subject of how much lean muscle mass these agents produce.
